Pravastatin in vivo reduces mononuclear cell migration through endothelial monolayers

S. Frigerio, M. Gelati, G. Boncoraglio, E. Ciusani, D. Croci, M. Curtis, E. Parati, A. Salmaggi

Research output: Contribution to journalArticlepeer-review


The objective was to evaluate pravastatin modulation on peripheral blood mononuclear cell (PBMC) migration across endothelial monolayers. Eleven hypercholesterolaemic patients were treated with pravastatin 20 mg/day. At baseline (T0), after 40 days (T40) and after 6 months (T 6 months) of treatment total serum cholesterol, low-density lipoprotein (LDL), high-density lipoprotein, triglycerides, C-reactive protein, as well as tumour necrosis factor-α(TNF-α) and metalloproteinases-9 plasma levels were evaluated. At the same time points the effect of pravastatin on migration of PBMCs through a monolayer of murine brain endothelial cells was studied both in basal conditions and after endothelial stimulation with recombinant mouse TNF-α10 ng/ml for 24 h. Seven volunteers were used as healthy controls. Significant decreases in total cholesterol, LDL and triglycerides as well as inhibition of transmigration were observed. PBMCs transmigration in patients prior to pravastatin therapy was higher than in healthy controls. These results suggest that pravastatin could be of benefit in a spectrum of diseases characterised by extravasation of PBMCs into the central nervous system.

Original languageEnglish
Pages (from-to)261-265
Number of pages5
JournalNeurological Sciences
Issue number4
Publication statusPublished - Sep 2006


  • Inflammation
  • Mononuclear cells
  • Pravastatin
  • Transmigration

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Pravastatin in vivo reduces mononuclear cell migration through endothelial monolayers'. Together they form a unique fingerprint.

Cite this